⭐️ Join our Board of Directors! ⭐️ Are you looking for a way to truly have an impact on the GRIN2B Community? GRIN2B Foundation is currently seeking individuals with a demonstrated connection to either the GRIN2B or rare disease community to join our Board of Directors. ⭐️ GRIN2B Foundation is a 501c3 nonprofit serving the GRIN2B community, whose mission is to drive and fund research; increase awareness; and provide support to affected individuals and families. ⭐️ We are seeking three new board members: Secretary Governance Chair Board Member at Large 📑 Apply here: https://forms.gle/DeNG9RG3xtf212NK7 ⭐️ Completed application forms must be submitted by July 31, 2025. Please contact elissa.taylor-bustillo@grin2b.com for any questions. (fb)

📣 Another day, another exciting press release from GRIN Therapeutics! GRIN Therapeutics, Inc., an affiliate company of Neurvati Neurosciences, issued a press release announcing an exclusive collaboration with Angelini Pharma to develop and commercialize investigational radiprodil outside North America. This collaboration combines Angelini Pharma’s global reach and focus on complex neurological disorders with GRIN Therapeutics’ expertise and capabilities in developing and advancing precision therapeutics for neurodevelopmental disorders. GRIN Therapeutics will continue to lead global development and retains exclusive rights for radiprodil in the United States, Canada, and Mexico, while Angelini Pharma will receive exclusive rights to commercialize radiprodil in the rest of the world. You can read the full press release here: https://neurvati.com/wp-content/uploads/GRINTx_AP_PR_21.5.25.pdf (fb)